Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024

Tenaya Therapeutics, Inc.

2022-Q3 EPS reported -$2.18

Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.
R&D expenses $23.8M, G&A $7.5M; net loss $30.7M ($0.74 per share).
Dosing started in Phase 1 trial for TN-301 (HDAC6 inhibitor for HFpEF); data expected in 2023.
Plans to submit IND for TN-201 (MYBPC3 gene therapy for HCM) by year-end 2022; IND for TN-401 in 2023.
USPTO granted patent for TN-201 covering AAV therapy with MYBPC3; patent for TN-301 HDAC6 inhibitor allowed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tenaya Therapeutics, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share., EPS $0.74 per share.

Period: third quarter ended September 30, 2022
Net income: Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share.
EPS: $0.74 per share
Result: reported results

Exact text from the filing

Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.